WO2020115974A1 - Composition destinée à la cavité buccale - Google Patents

Composition destinée à la cavité buccale Download PDF

Info

Publication number
WO2020115974A1
WO2020115974A1 PCT/JP2019/034920 JP2019034920W WO2020115974A1 WO 2020115974 A1 WO2020115974 A1 WO 2020115974A1 JP 2019034920 W JP2019034920 W JP 2019034920W WO 2020115974 A1 WO2020115974 A1 WO 2020115974A1
Authority
WO
WIPO (PCT)
Prior art keywords
mass
component
less
composition
present
Prior art date
Application number
PCT/JP2019/034920
Other languages
English (en)
Japanese (ja)
Inventor
陽介 内野
綾 荻原
Original Assignee
花王株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 花王株式会社 filed Critical 花王株式会社
Priority to CN201980080023.9A priority Critical patent/CN113164353B/zh
Publication of WO2020115974A1 publication Critical patent/WO2020115974A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the present invention relates to a composition for oral cavity.
  • erythritol as contained in the oral composition described in Patent Document 1, is an effective component for suppressing or dissociating the agglutination reaction between bacteria in the oral cavity, and is a biofilm. It is known to be excellent not only in the effect of inhibiting the formation but also in the effect of removing the biofilm formed in the spaces between the teeth and the periodontal pockets.
  • Patent Literature 2 discloses an oral composition containing an acylamino anionic surfactant, a nonionic surfactant, and isopropylmethylphenol at a specific blending ratio together with such potassium nitrate. By enhancing the dissolution property, the nerve blunting effect is sufficiently expressed, and the pain caused by hypersensitivity of dentin is reduced.
  • Patent Document 1 Japanese Patent Laid-Open No. 2005-29484
  • Patent Document 2 Japanese Patent Laid-Open No. 2016-222579
  • the present invention comprises the following components (A), (B), (C) and (D): (A) Erythritol 3% by mass or more and 33% by mass or less (B) Potassium compound (C) N-acyl amino acid having a hydrocarbon group having 14 to 18 carbon atoms or an alkali metal salt thereof (D) Water, and a component (
  • the present invention relates to a composition for oral cavity in which the mass ratio ((D)/(A)) between the content of D) and the content of component (A) is 1 or more and 10 or less.
  • the present invention relates to a composition for oral cavity which has an excellent effect of removing an oral biofilm by erythritol and an excellent effect of suppressing hypersensitivity of dentin.
  • the present inventor has conducted various studies and, while containing a specific amount of erythritol and containing a potassium compound such as potassium nitrate, further uses an N-acylamino acid having a specific hydrocarbon group or a salt thereof, and By adjusting erythritol and water to a specific mass ratio, it is possible to effectively block the oral biofilm removal effect of erythritol and block the opening of dentinal tubules on the surface of exposed dentin. In addition, it was found that an oral composition capable of effectively preventing pain caused by hypersensitivity of dentin can be obtained.
  • the opening of the dentin tubule on the surface of the exposed dentin can be effectively blocked while erythritol sufficiently exerts the effect of dispersing the oral biofilm. That is, the composition for oral cavity of the present invention is a highly useful composition having both the effect of removing the biofilm in the oral cavity and the effect of suppressing pain caused by hypersensitivity of dentin.
  • FIG. 1 is an electron micrograph of the surface of dentin when the oral composition of Example 1 was used.
  • FIG. 2 is an electron micrograph of the surface of dentin when the oral composition of Comparative Example 2 was used.
  • dentinal tubule is also referred to as “dentin tubule”.
  • blocking dentinal tubules means physically blocking dentin tubules, not only covering the opening of the dentin tubule on the surface of the dentin, but also in the tubule near the surface of the dentin tubule. It is also meant to include the state of filling and covering (closing).
  • the oral composition of the present invention contains 3% by mass or more and 33% by mass or less of erythritol as the component (A).
  • the component (C) described later by suppressing the agglutination reaction between the bacteria or by dissociating the agglutination between the bacteria, the formation of the biofilm is inhibited and the teeth and teeth or teeth A biofilm that has already formed can be removed to a narrow area such as a gap such as a peripheral pocket, and a sufficient oral biofilm can be obtained while having a pain suppressing effect due to excellent dentin hyperesthesia. It is possible to exert a dispersion effect.
  • the content of the component (A) is 3% by mass or more, and preferably 5% by mass or more, in the composition for oral cavity of the present invention, from the viewpoint of sufficiently exerting the biofilm removal effect. It is preferably 8% by mass or more, more preferably 10% by mass or more, still more preferably 20% by mass or more.
  • the content of the component (A) depends on the component (B) so as to effectively prevent the pain caused by hypersensitivity of dentin from being enhanced by osmotic stimulation caused by dissolution in water. From the viewpoint of ensuring a good effect of suppressing pain caused by dentin hypersensitivity, it is 33% by mass or less, preferably 32% by mass or less, more preferably in the oral composition of the present invention.
  • the content of the component (A) in the oral composition of the present invention is 3% by mass or more and 33% by mass or less, preferably 5 to 32% by mass, more preferably 8 to 31% by mass. %, more preferably 10 to 30% by mass, still more preferably 20 to 30% by mass.
  • the oral composition of the present invention contains a potassium compound as the component (B). With this, while ensuring the effect of removing the biofilm by the above component (A), after applying the oral composition of the present invention to the oral cavity, it rapidly releases potassium ions to form a composition with the component (C) described below. It quickly forms a potassium salt of N-acyl amino acid having a hydrocarbon group having 14 to 18 carbon atoms, which is stably dissolved in a substance, and the salt acts on the surface of dentin to effectively block the dentinal tubule. However, it is possible to exert an effect of suppressing an increase in pain caused by hypersensitivity of dentin due to osmotic stimulation caused by dissolution of the component (A) in water.
  • the effect of blocking the dentinal tubule in combination with the above component (C) is enhanced to suppress pain caused by dentin hypersensitivity.
  • one or more potassium compounds selected from potassium nitrate, tripotassium citrate, potassium acetate and potassium hydroxide are preferable, and among them, one or two selected from potassium nitrate and potassium hydroxide.
  • the seeds are more preferable, and it is preferable to use these in combination.
  • the component (B) means a potassium compound other than the component (C) described later.
  • the content of the component (B) is preferably 0.001% by mass or more in the oral composition of the present invention from the viewpoint of promoting rapid release of potassium ions after application of the composition to the oral cavity. %, more preferably 0.01% by mass or more, further preferably 0.05% by mass or more, even more preferably 2% by mass or more, still more preferably 3% by mass or more, and It is preferably 4% by mass or more.
  • the content of the component (B) is preferably 10% by mass or less, more preferably 8% by mass or less in the oral composition of the present invention from the viewpoint of preventing off-taste. , And more preferably 7% by mass or less.
  • the content of the component (B) in the oral composition of the present invention is preferably 0.001% by mass or more and 10% by mass or less, more preferably 0.01 to 10% by mass, and further The amount is preferably 0.05 to 10% by mass, more preferably 2% by mass or more and 10% by mass or less, still more preferably 3 to 8% by mass, and further preferably 4 to 7% by mass. ..
  • the mass ratio ((B)/(A)) between the content of the component (A) and the content of the component (B) is due to the removal effect of the intraoral biofilm and the dissolution of the component (A) in water.
  • the oral composition of the present invention contains, as the component (C), an N-acyl amino acid having a hydrocarbon group having 14 to 18 carbon atoms or an alkali metal salt thereof.
  • the component (C) when the oral composition of the present invention is applied to the oral cavity, it has a hydrocarbon group having 14 to 18 carbon atoms together with the potassium ion released by the component (B).
  • An N-acyl amino acid potassium salt which forms a N-acyl amino acid potassium salt promptly or has a potassium ion abundantly present in the oral composition by the component (B) and has a hydrocarbon group having 14 to 18 carbon atoms.
  • the salt of the present invention can be stabilized and the salt of the present invention can be sufficiently spread throughout the oral cavity in the composition of the present invention to easily reach the desired dentin surface. Furthermore, when such a salt reaches the surface of dentin, the substitution of the potassium salt of the N-acyl amino acid with the calcium salt of the N-acyl amino acid proceeds rapidly, and the hydrocarbon group having 14 to 18 carbon atoms is replaced. Since the precipitate of the calcium salt of the N-acyl amino acid has firmly adhered to the surface of the dentin, the dentinal tubule can be effectively blocked and the pain suppressing effect can be effectively enhanced. Further, the above component (A There is no fear of impeding the biofilm removal effect of ).
  • amino acid portion of the N-acyl amino acid having a hydrocarbon group having 14 to 18 carbon atoms in the component (C) one selected from glutamic acid, glycine and alanine from the viewpoint of exerting an excellent dentinal tubule blocking effect, or Two or more types are preferable, and one or two types selected from glutamic acid and glycine are more preferable, and glycine is even more preferable, from the viewpoint of blocking dentinal tubules more effectively and quickly.
  • these amino acid moieties may be any of D-form, L-form or a mixture of D-form and L-form, and preferably L-form.
  • the acyl group of the N-acyl amino acid in the component (C) has a hydrocarbon group having 14 to 18 carbon atoms from the viewpoint of exhibiting an excellent dentinal tubule blocking effect.
  • the N-acyl amino acid having a hydrocarbon group having 14 to 18 carbon atoms or its alkali metal salt is derived from a saturated or unsaturated linear or branched fatty acid or a mixed fatty acid thereof. More preferably, it has a hydrocarbon group having 14 to 16 carbon atoms.
  • acyl group having a hydrocarbon group having such a carbon number a plurality of types of the hydrocarbon group having the above-mentioned carbon number may be mixed, but from the viewpoint of sufficiently exhibiting the excellent effect of blocking the opening of the dentinal tubule.
  • One or more selected from a myristoyl group, a palmitoyl group and a stearoyl group are preferable, and a myristoyl group is more preferable.
  • Examples of the salt of the alkali metal salt of the N-acyl amino acid having a hydrocarbon group having 14 to 18 carbon atoms in the component (C) include sodium and potassium, and potassium is preferable.
  • the content of the component (C) is effective by forming a potassium salt which dissolves rapidly and stably in the composition together with the potassium ion released by the component (B), and the salt acts on the surface of the dentin. From the viewpoint of effectively blocking pain by effectively blocking dentinal tubules, it is preferably 0.01% by mass or more, more preferably 0.05% by acid equivalent in the oral composition of the present invention. It is at least mass%, more preferably at least 0.1 mass%. Moreover, the content of the component (C) is preferably 2% by mass or less, more preferably 1.5% by acid equivalent in the oral composition of the present invention from the viewpoint of ensuring a good flavor. It is not more than 1% by mass, preferably not more than 1% by mass.
  • the content of the component (C) in the oral composition of the present invention is, in terms of acid, preferably 0.01% by mass or more and 2% by mass or less, more preferably 0.05 to 1. It is 5% by mass, more preferably 0.1 to 1% by mass.
  • the “acid conversion amount” means that the content of the component (C) is expressed as a content converted into an N-acyl amino acid having a hydrocarbon group having 14 to 18 carbon atoms.
  • an N-acyl amino acid or an alkali metal salt thereof having an acyl group capable of containing a hydrocarbon group having a carbon number other than the above-mentioned number of carbon atoms, such as a cocoyl group, mixed with a plurality of hydrocarbon groups having the above-mentioned carbon number is used.
  • the content of the N-acyl amino acid having a hydrocarbon group of the above carbon number or its alkali metal salt is the content of the above component (C). Good.
  • the mass ratio ((C)/(A)) between the acid equivalent amount of the component (C) and the content of the component (A) is due to the removal effect of the oral biofilm and the dissolution of the component (A) in water. From the viewpoint of satisfactorily having the effect of effectively suppressing the increase in pain due to dentin hypersensitivity by the osmotic stimulus, it is preferably 0.001 or more, and more preferably 0. It is 0.004 or more, more preferably 0.008 or more, preferably 0.035 or less, more preferably 0.03 or less, and further preferably 0.02 or less.
  • the oral composition of the present invention contains water as a component (D).
  • water By adjusting the water content, it is possible to effectively prevent the pain caused by dentin hypersensitivity from being enhanced by the osmotic stimulation caused by the dissolution of the component (A) into the component (D). To do. Further, the potassium ion released from the component (B) is allowed to be present in the composition, and the potassium salt of the N-acyl amino acid having the above-mentioned specific carbon number, which shows stable solubility by the components (B) and (C), is obtained. It becomes possible to effectively block the dentinal tubules while allowing the dentin tubules to exist and fully spread to every corner of the oral cavity, and the biofilm removing effect can be sufficiently exerted.
  • the content of the component (D) is such that the osmotic stimulation caused by the dissolution of the component (A) in the component (D) is suppressed, and the stable solubility is obtained by the components (B) and (C).
  • the composition for oral cavity it is preferably 8% by mass or more, more preferably 10% by mass or more, further preferably 12% by mass or more, even more preferably 15% by mass or more, still more preferably Is 33% by mass or more, more preferably 34% by mass or more, even more preferably 40% by mass or more, still more preferably 45% by mass or more, preferably less than 60% by mass, It is more preferably 55% by mass or less, and further preferably 50% by mass or less.
  • the mass ratio ((D)/(A)) between the content of the component (D) and the content of the component (A) ensures that the component (A) has an excellent biofilm removal effect.
  • it is 1 or more, preferably 2 or more, and more preferably 3 Or more, more preferably 3.5 or more, 10 or less, preferably 9 or less, and more preferably 5 or less.
  • the oral composition of the present invention may further contain a fatty acid divalent metal salt (E) having a hydrocarbon group having 12 to 18 carbon atoms. This can further enhance the effect of suppressing pain caused by hypersensitivity of dentin.
  • the component (E) is derived from a saturated fatty acid having 12 to 18 carbon atoms and is composed of two saturated fatty acids and a divalent metal.
  • Specific examples of the derived saturated fatty acid include lauric acid, myristic acid, pentadecyl acid, palmitic acid, margaric acid, and stearic acid. Among them, lauric acid, myristic acid, palmitic acid and stearic acid are preferable, and lauric acid, myristic acid and stearic acid are more preferable.
  • the two saturated fatty acids constituting the component (E) are preferably the same.
  • the divalent metal include zinc, calcium, magnesium, strontium and barium.
  • zinc, calcium and magnesium are preferable, and zinc and calcium are more preferable, from the viewpoints of effectively enhancing the pain suppressing effect caused by dentin hypersensitivity and the applicability in the oral cavity.
  • zinc stearate is preferable as the component (E).
  • the content of the component (E) is preferably 0.1 to 3 in the oral composition of the present invention, from the viewpoint of enhancing the sealing property of the opening of the dentin tubule and maintaining a good flavor. %, more preferably 0.2 to 2% by mass, further preferably 0.4 to 1.8% by mass.
  • the oral composition of the present invention may further contain maltitol (F).
  • maltitol (F) unnecessary crystal growth of the component (A) can be effectively suppressed, an excellent biofilm removal effect can be ensured, and the dissolution of the component (A) into the component (D) is a factor.
  • the osmotic stimulus effectively suppresses the enhancement of pain due to dentin hypersensitivity, while maintaining high stability of the composition to ensure a good appearance, and also good. It is possible to secure the perfect flavor.
  • the content of the component (F) is preferably 1 in the oral composition of the present invention from the viewpoint of effectively ensuring the excellent biofilm removal effect of the component (A) and ensuring a good appearance.
  • To 30% by mass more preferably 3 to 20% by mass, and further preferably 5 to 15% by mass.
  • the oral composition of the present invention when the oral composition of the present invention is a toothpaste composition, it may contain 10% by mass or less of an abrasive, or does not contain an abrasive.
  • abrasives include abrasive silica, dibasic calcium phosphate dihydrate and anhydride, calcium pyrophosphate, calcium carbonate, alumina, aluminum hydroxide, magnesium acetate, dibasic magnesium phosphate, magnesium acetate, and triphosphoric acid.
  • abrasives such as magnesium and zeolite may be used.
  • an abrasive containing at least abrasive silica is preferable, and an abrasive consisting only of abrasive silica is more preferable.
  • the abrasive silica is one having an oil absorption of 50 to 150 mL/100 g, and the oil absorption is the amount of oil that can be supported by silica.
  • the measuring method is JIS K5101-13-2 (2004). Established), specify by the amount of boiled linseed oil absorbed.
  • the content of the abrasive is preferably in the oral composition of the present invention from the viewpoint of the effect of blocking dentinal tubules, from the viewpoint of suppressing the further hypersensitivity of the user of the present invention due to the composition of the present invention. It is 10% by mass or less, more preferably 8% by mass or less, still more preferably 4% by mass or less, and imparts a good flavor while achieving both an excellent biofilm removal effect and a dentinal tubule sealing effect. From the viewpoint of ensuring also the above, it is preferably more than 0 mass%, more preferably 2 mass% or more.
  • the oral composition of the present invention may further contain a wetting agent in addition to the above components.
  • a wetting agent include one or more selected from glycerin, propylene glycol, polyethylene glycol, sorbitol, xylitol and lactol, and one or more selected from sorbitol, glycerin, xylitol and propylene glycol. Is preferred, and one or two selected from sorbitol and propylene glycol is more preferred.
  • the total content of the wetting agent is preferably in the oral composition of the present invention, from the viewpoint of ensuring good storage stability and flavor of the composition while exhibiting a quick and excellent blocking effect for dentin tubules. 5 mass% or more, more preferably 8 mass% or more, preferably 60 mass% or less, more preferably 45 mass% or less, further preferably 40 mass% or less, and even more preferably It is 35 mass% or less.
  • the oral composition of the present invention may further contain a binder.
  • a binder one or more selected from sodium alginate, sodium carboxymethyl cellulose, carrageenan, xanthan gum, sodium polyacrylate, hydroxyethyl cellulose, hydroxypropyl cellulose, pectin, tragacanth gum, gum arabic, and guar gum.
  • sodium alginate, sodium carboxymethyl cellulose, carrageenan, xanthan gum, and hydroxyethyl cellulose is preferable, and one or more selected from sodium carboxymethyl cellulose and carrageenan is particularly preferable.
  • the content of such a binder in the oral composition of the present invention is preferably 0.2% by mass or more, more preferably 0%. It is 0.4% by mass or more, preferably 3% by mass or less, more preferably 2.5% by mass or less, and further preferably 1.8% by mass or less.
  • the oral composition of the present invention may further contain an amphoteric surfactant as the component (G).
  • amphoteric surfactants include one or more selected from alkylamidopropyl betaine such as coconut oil fatty acid amide propyl betaine and alkyl hydroxysulfobetaine such as lauryl hydroxysulfobetaine.
  • the content of the amphoteric surfactant as the component (G) is preferably 0.05 mass in the oral composition of the present invention from the viewpoint of appropriately controlling the osmotic pressure stimulation of the component (A) by its foaming property. % Or more, more preferably 0.1% by mass or more, further preferably 0.25% by mass or more, preferably 3% by mass or less, more preferably 2% by mass or less, and further preferably Is 0.8 mass% or less.
  • the mass ratio ((G)/(A)) between the content of the component (G) and the content of the component (A) is such that the component (A) can maintain an excellent biofilm removal effect.
  • it is preferably 0.001 or more, more preferably 0.5 or more, and further preferably 0.1 or more. , Preferably 0.05 or less.
  • the oral composition of the present invention is a toothpaste composition
  • a thickening silica is silica having an oil absorption of 200 to 400 mL/100 g.
  • the oil absorption indicates the amount of oil that can be supported by silica
  • the measuring method is specified by JIS K5101-13-2 (established in 2004) by the amount of boiled linseed oil absorbed.
  • the content of the thickening silica in the oral composition of the present invention is preferably 0.1 to 20% by mass, more preferably 1 to 10% by mass, and further preferably 2 to 8% by mass. is there.
  • anionic surfactants such as sodium lauryl sulfate and sodium lauroylmethyl taurine, cationic surfactants, coconut oil fatty acid amide propyl betaine.
  • amphoteric surfactants polyoxyethylene hydrogenated castor oil, nonionic surfactants such as sucrose fatty acid esters, sorbitan fatty acid esters, and other surfactants; sweeteners such as saccharin sodium; perfumes; dyes; Can be included.
  • tin fluoride sodium fluoride
  • a fluoride ion supply compound such as ammonium fluoride
  • a fluoride such as sodium monofluorophosphate
  • titanium oxide titanium oxide
  • aluminum lactate calcium phosphate
  • Other components such as apatite and arginine-calcium carbonate may also be included.
  • the potassium contained in the oral composition of the present invention exists in the ionic form or the salt form in the oral composition of the present invention.
  • such potassium is present as potassium ions released from component (B), when component (C) is a potassium salt, as potassium forming such salt.
  • the total amount of potassium present from the viewpoint of promoting rapid release of potassium ions after application of the composition into the oral cavity, the oral cavity of the present invention In the composition for use, it is preferably 0.05 mass% or more, more preferably 0.1 mass% or more, and further preferably 0.5 mass% or more.
  • the total amount of potassium present in the composition for oral cavity of the present invention is preferably 6% by mass or less, more preferably 4% by mass or less, and further preferably from the viewpoint of preventing off-taste. It is 2 mass% or less.
  • the total amount of potassium present in the composition for oral cavity of the present invention is preferably 0.05% by mass or more and 6% by mass or less, more preferably 0.1 to 4% by mass, and further preferably 0.1. It is 5 to 2 mass %.
  • the total amount of potassium present in the oral composition can be measured by ion chromatography, ICP emission spectroscopy, or the like.
  • the mass ratio ((C)/potassium) between the content of the component (C) and the total amount of potassium present is such that the rapid release of potassium ions after application of the composition into the oral cavity and the taste From the viewpoint of preventing the feeling of being felt, it is preferably 0.01 or more, more preferably 0.05 or more, still more preferably 0.08 or more, preferably 1 or less, more preferably 0. It is 0.5 or less, more preferably 0.3 or less.
  • the pH of the composition for oral cavity of the present invention at 25° C. is preferably 6.5 or more, more preferably 7 or more, from the viewpoint of promoting the formation of a salt by the components (B) and (C). More preferably, it is 7.5 or more, preferably 9.5 or less, more preferably 9 or less, and further preferably from the viewpoint of ensuring good flavor while preventing discoloration of the composition and modulation of the fragrance. Is 8.5 or less.
  • the pH of the oral composition of the present invention is a value measured at 25° C. using a pH electrode, and when the oral composition of the present invention is a liquid toothpaste composition, the composition should be diluted. When the oral composition of the present invention is a toothpaste composition, it is measured without adjusting to an aqueous solution having a concentration of 10% by mass with purified water composed of ion-exchanged water or distilled water. Means the value
  • the oral composition of the present invention exhibits an excellent biofilm removal effect, and can effectively prevent pain caused by dentin hypersensitivity, and therefore, an oral composition for dentin hypersensitivity. That is, it can be widely used as a dentin hypersensitivity reducing agent or a preventive agent.
  • the method for producing the oral cavity composition of the present invention is not particularly limited, and the above components may be appropriately mixed by a conventional method. Specifically, for example, it is obtained in the step (I) and the step (I) in which a mixture containing the component (B) and at least a part of the component (D) and having a pH at 25° C. of 9 or more is obtained and heated. It is preferable to include a step (II) of mixing the component (C) with the mixture, and a step (III) of adding the component (A) to the mixture obtained in the step (II).
  • the heating temperature of the mixture in step (I) is preferably 40° C. or higher, more preferably 50° C. or higher, even more preferably 55° C. or higher, preferably 100° C.
  • step (II) it is preferable to mix other water-soluble components with the mixture obtained in step (I).
  • the other water-soluble component include a water-soluble component such as a fluoride ion supplying compound and saccharin sodium. Further, a binder may be added and mixed.
  • step (III) it is preferable to add the component (A) and powders such as a surfactant and an abrasive.
  • the rest of the component (D) may be added and mixed.
  • a step (IV) of adding a fragrance to the mixture obtained in the step (III) and mixing at room temperature of 15 to 30° C. may be provided.
  • the present invention further discloses the following oral compositions.
  • the content of the component (A) is preferably 5% by mass or more, more preferably 8% by mass or more, further preferably 10% by mass or more, still more preferably 20% by mass or more. Yes, preferably 32% by mass or less, more preferably 31% by mass or less, and further preferably 30% by mass or less, the oral composition according to the above [1].
  • the mass ratio ((B)/(A)) of the content of the component (A) to the content of the component (B) is preferably 0.1 or more, more preferably 0.13 or more. Yes, more preferably 0.15 or more, still more preferably 0.18 or more, even more preferably 0.2 or more, preferably 1.5 or less, more preferably 1.25 or less. And more preferably 1 or less, and even more preferably 0.8 or less, [1] or [2].
  • the amino acid portion of the N-acyl amino acid in the component (C) is preferably one or more selected from glutamic acid, glycine and alanine, and more preferably one or two selected from glutamic acid and glycine. And more preferably glycine, the composition for oral cavity according to any one of the above [1] to [3].
  • the acyl group of the N-acyl amino acid in the component (C) is preferably one or more selected from myristoyl group, palmitoyl group and stearoyl group, and more preferably myristoyl group.
  • the content of the component (C) in terms of acid is preferably 0.01% by mass or more, more preferably 0.05% by mass or more, and further preferably 0.1% by mass or more. It is preferably 2% by mass or less, more preferably 1.5% by mass or less, still more preferably 1% by mass or less, and the oral composition according to any one of the above [1] to [5].
  • the mass ratio ((C)/(A)) between the acid equivalent amount of the component (C) and the content of the component (A) is preferably 0.001 or more, more preferably 0.004 or more. And more preferably 0.008 or more, preferably 0.035 or less, more preferably 0.03 or less, still more preferably 0.02 or less.
  • No. 1 oral composition is preferably 0.01% by mass or more, more preferably 0.05% by mass or more, and further preferably 0.1% by mass or more. It is preferably 2% by mass or less, more preferably 1.5% by mass or less, still more preferably 1% by mass or less,
  • the content of the component (D) is preferably 8% by mass or more, more preferably 10% by mass or more, further preferably 12% by mass or more, still more preferably 15% by mass or more. Yes, even more preferably 33 mass% or more, even more preferably 34 mass% or more, even more preferably 40 mass% or more, even more preferably 45 mass% or more, preferably 60 mass% %, more preferably 55% by mass or less, and further preferably 50% by mass or less, the oral composition according to any one of the above [1] to [7].
  • the mass ratio ((D)/(A)) of the content of the component (D) and the content of the component (A) is preferably 2 or more, more preferably 3 or more, and further preferably Is 3.5 or more, preferably 9 or less, more preferably 5 or less, the oral composition according to any one of the above [1] to [8].
  • the content of the component (E) is preferably 0.1 to 3% by mass, more preferably 0.2 to 2% by mass, and still more preferably 0.4 to 1.8% by mass.
  • the composition for oral cavity according to any one of [1] to [10] above.
  • Maltitol (F) is further contained, and the content of the component (F) is preferably 1 to 30% by mass, more preferably 3 to 20% by mass, and further preferably 5 to 15% by mass. %, The oral composition according to any one of the above [1] to [11].
  • the content of the component (B) is preferably 0.001% by mass or more, more preferably 0.01% by mass or more, still more preferably 0.05% by mass or more, even more preferably Is 2% by mass or more, more preferably 3% by mass or more, even more preferably 4% by mass or more, preferably 10% by mass or less, more preferably 8% by mass or less, and
  • composition for oral cavity [15] The mass ratio ((G)/(A)) of the content of the component (G) and the content of the component (A) is preferably 0.001 or more, more preferably 0.5 or more. Yes, more preferably 0.1 or more, preferably 0.05 or less, the oral composition according to the above [14].
  • step (I) Component (B) and step (I) containing at least a part of component (D) and having a pH at 25° C. of 9 or more and heating the mixture, and the mixture obtained in step (I)
  • the method includes a step (II) of mixing (C) and a step (III) of adding the component (A) to the mixture obtained in the step (II), preferably 15 to 30° C. after the step (III).
  • the method for producing an oral composition according to any one of [1] to [15] above, which comprises the step (IV) of adding a fragrance to the mixture obtained in the step (III) and mixing the mixture at room temperature.
  • Examples 1 to 11 Comparative Examples 1 to 6
  • the oral compositions shown in Tables 1 and 2 were produced by mixing the respective components by the above production method.
  • the contents of the component (C) in Tables 1 and 2 are shown in terms of acid.
  • Each of the obtained compositions was evaluated according to the methods and criteria shown below.
  • Example 1 1 g of each composition was placed on a toothbrush (Deep Clean Ultra Compact Ordinary, manufactured by Kao Corporation), the dentin sample was brushed for 1 minute, and then the sample was washed with distilled water for 10 seconds. Platinum was vapor-deposited on the surface of the sample after washing, and the dentin surface was photographed at a magnification of 2000 using an electron microscope (VE-7800, manufactured by KEYENCE, accelerating voltage 2 kV). The condition was evaluated. Electron micrographs of Example 1 and Comparative Example 2 are shown in FIGS. 1 and 2, respectively. As shown in FIG. 1, in Example 1, the openings of the dentinal tubules were sufficiently covered, whereas in Comparative Example 2 shown in FIG. 2, only a slight amount of deposits could be confirmed on the surface of the dentin. It can be seen that the ivory tubules are almost exposed.
  • sucrose was added so as to be a 5 mass% solution, and then stirred using a stirring device (voltex, manufactured by Nippon Genetics Co., Ltd.) to prepare a plaque model test solution.
  • a stirring device voltage, manufactured by Nippon Genetics Co., Ltd.
  • one side of the HAp substrate was mirror-polished using 40 ⁇ m, 12 ⁇ m, and 3 ⁇ m polishing paper, and then immersed in 1N HCl for 1 minute for acid deashing treatment.
  • the treated HAp plate is washed with ion-exchanged water, dried, put in a 24-well plate, and 1 mL of each of the above-prepared plaque model test solutions is added, and then stored in a plastic case together with a CO 2 pack to anaerobically Under the conditions, the cells were cultured at 37° C. for 48 hours.
  • AA Plaque removability is sufficiently high (remaining plaque rate less than 40%)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition destinée à la cavité buccale, qui présente un excellent effet d'élimination de biofilm buccal au moyen d'érythritol, tout en présentant un excellent effet de suppression de l'hyperesthésie de la dentine. La présente invention concerne une composition destinée à la cavité buccale, qui contient les constituants (A), (B), (C) et (D) décrits ci-après, et qui est conçue de telle sorte que le rapport de masse du constituant (D) au constituant (A), à savoir (D)/(A) est compris entre 1 et 10 (inclus). Constituant (A) : de 3 % en masse à 33 % en masse (inclus) d'érythritol Constituant (B) : un composé de potassium Constituant (C) : un acide N-acyl aminé ayant un groupe hydrocarboné comportant 14 à 18 atomes de carbone, ou un sel de métal alcalin de ce dernier Constituant (D) : de l'eau
PCT/JP2019/034920 2018-12-04 2019-09-05 Composition destinée à la cavité buccale WO2020115974A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201980080023.9A CN113164353B (zh) 2018-12-04 2019-09-05 口腔用组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-227516 2018-12-04
JP2018227516 2018-12-04

Publications (1)

Publication Number Publication Date
WO2020115974A1 true WO2020115974A1 (fr) 2020-06-11

Family

ID=70973718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/034920 WO2020115974A1 (fr) 2018-12-04 2019-09-05 Composition destinée à la cavité buccale

Country Status (4)

Country Link
JP (1) JP7337610B2 (fr)
CN (1) CN113164353B (fr)
TW (1) TWI832898B (fr)
WO (1) WO2020115974A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023084922A1 (fr) * 2021-11-11 2023-05-19 花王株式会社 Composition pour cavité buccale

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000154127A (ja) * 1998-11-18 2000-06-06 Lion Corp 口腔用組成物
JP2011168510A (ja) * 2010-02-17 2011-09-01 Lion Corp 口腔用組成物
JP2012036172A (ja) * 2010-07-12 2012-02-23 Kao Corp 歯磨組成物
JP2013001648A (ja) * 2011-06-13 2013-01-07 Kao Corp 歯磨組成物
JP2013112613A (ja) * 2011-11-25 2013-06-10 Lion Corp 歯磨剤組成物
JP2014062066A (ja) * 2012-09-21 2014-04-10 Kao Corp 口腔用組成物
JP2014125443A (ja) * 2012-12-26 2014-07-07 Kao Corp 口腔用組成物
JP2015117205A (ja) * 2013-12-18 2015-06-25 花王株式会社 歯磨組成物
JP2015124216A (ja) * 2013-12-27 2015-07-06 花王株式会社 象牙質知覚過敏用口腔用組成物
JP2018039742A (ja) * 2016-09-06 2018-03-15 花王株式会社 口腔用組成物
KR20180113471A (ko) * 2017-04-06 2018-10-16 주식회사 엘지생활건강 치약 조성물

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000154127A (ja) * 1998-11-18 2000-06-06 Lion Corp 口腔用組成物
JP2011168510A (ja) * 2010-02-17 2011-09-01 Lion Corp 口腔用組成物
JP2012036172A (ja) * 2010-07-12 2012-02-23 Kao Corp 歯磨組成物
JP2013001648A (ja) * 2011-06-13 2013-01-07 Kao Corp 歯磨組成物
JP2013112613A (ja) * 2011-11-25 2013-06-10 Lion Corp 歯磨剤組成物
JP2014062066A (ja) * 2012-09-21 2014-04-10 Kao Corp 口腔用組成物
JP2014125443A (ja) * 2012-12-26 2014-07-07 Kao Corp 口腔用組成物
JP2015117205A (ja) * 2013-12-18 2015-06-25 花王株式会社 歯磨組成物
JP2015124216A (ja) * 2013-12-27 2015-07-06 花王株式会社 象牙質知覚過敏用口腔用組成物
JP2018039742A (ja) * 2016-09-06 2018-03-15 花王株式会社 口腔用組成物
KR20180113471A (ko) * 2017-04-06 2018-10-16 주식회사 엘지생활건강 치약 조성물

Also Published As

Publication number Publication date
TWI832898B (zh) 2024-02-21
JP7337610B2 (ja) 2023-09-04
JP2020094030A (ja) 2020-06-18
TW202031240A (zh) 2020-09-01
CN113164353A (zh) 2021-07-23
CN113164353B (zh) 2023-08-08

Similar Documents

Publication Publication Date Title
JP2010222325A (ja) 歯牙の象牙細管封鎖剤及び口腔用組成物
JP6276028B2 (ja) 象牙質知覚過敏用口腔用組成物
JP5720546B2 (ja) 歯磨剤組成物及び歯牙の再石灰化促進剤
WO2020115974A1 (fr) Composition destinée à la cavité buccale
JP2019116442A (ja) 歯磨剤組成物
JP6038567B2 (ja) 口腔用組成物
JP7075291B2 (ja) 口腔用組成物
JP7281423B2 (ja) 口腔用組成物
JP6910333B2 (ja) 口腔用組成物
JP7200933B2 (ja) 歯磨剤組成物
JP6118547B2 (ja) 口腔用組成物
EP2859881B1 (fr) Composition orale
JP6825339B2 (ja) 口腔用組成物
TWI842814B (zh) 口腔用組合物
CN109789077B (zh) 口腔用组合物
WO2017104664A1 (fr) Composition liquide à usage oral
WO2018221609A1 (fr) Composition de dentifrice
JP7088179B2 (ja) 歯磨剤組成物
JP7073402B2 (ja) 口腔用組成物
TW201800086A (zh) 口腔用組合物
JP7078043B2 (ja) 歯磨剤組成物
WO2022059642A1 (fr) Composition de dentifrice
KR20160010667A (ko) 탄산수소나트륨과 퀼라야 추출물을 함유하는 치약 조성물
RU2240777C1 (ru) Композиция зубной пасты
JPWO2019230710A1 (ja) 口腔用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19892963

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19892963

Country of ref document: EP

Kind code of ref document: A1